Aleve-D Sinus and Cold

Manufacturer
Bayer HealthCare LLC.
Effective date
2025-12-04
Label type
HUMAN OTC DRUG LABEL
Version
8
Source
full-release
Hydrated at
2026-06-01 01:19:51

Label at a glance#

ProductAleve-D Sinus and Cold
Active ingredientPSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM
Label structure17 sections

Indications and uses

Uses temporarily relieves these cold, sinus, and flu symptoms: • sinus pressure • minor body aches and pains • headache • nasal and sinus congestion (promotes sinus drainage and restores freer breathing through the nose) • fever

Dosage and administration

Directions • do not take more than directed • the smallest effective dose should be used • swallow whole ; do not crush or chew • drink a full glass of water with each dose • adults and children 12 years and older : 1 caplet every 12 hours ; do not take more than 2 caplets in 24 hours • children under 12 years: do not use

Label contents#

Full prescribing information#

Drug Facts

SPL UNCLASSIFIED SECTION

Drug Facts

OTC - ACTIVE INGREDIENT SECTION

Active ingredients

(in each caplet)

Naproxen sodium 220 mg

(naproxen 200 mg) (NSAID)*

Pseudoephedrine HCl 120 mg, extended-release

*nonsteroidal anti-inflammatory drug

OTC - PURPOSE SECTION

Purposes

Pain reliever/fever reducer

Nasal decongestant

Uses

INDICATIONS & USAGE SECTION

Uses temporarily relieves these cold, sinus, and flu symptoms: • sinus pressure • minor body aches and pains • headache • nasal and sinus congestion (promotes sinus

drainage and restores freer breathing through the nose) • fever

WARNINGS SECTION

Allergy alert: Naproxen sodium may cause a severe allergic

reaction, especially in people allergic to aspirin. Symptoms

may include: • hives • facial swelling • asthma (wheezing) • shock • skin reddening • rash • blisters

If an allergic reaction occurs, stop use and seek medical help

right away.

Stomach bleeding warning: This product contains an NSAID,

which may cause severe stomach bleeding. The chance is

higher if you:

• are age 60 or older

• have had stomach ulcers or bleeding problems

• take a blood thinning (anticoagulant) or steroid drug

• take other drugs containing prescription or nonprescription

NSAIDs (aspirin, ibuprofen, naproxen, or others)

• have 3 or more alcoholic drinks every day while using

this product

• take more or for a longer time than directed

Heart attack and stroke warning: NSAIDs, except aspirin, increase the risk of heart attack, heart failure, and stroke. These can be fatal. The risk is higher if you use more than directed or for longer than directed.

OTC - DO NOT USE SECTION

Do not use

• if you have ever had an allergic reaction to any other pain

reliever/fever reducer

• right before or after heart surgery

• if you are now taking a prescription monoamine oxidase

inhibitor (MAOI) (certain drugs for depression, psychiatric,

or emotional conditions, or Parkinson’s disease), or for

2 weeks after stopping the MAOI drug. If you do not know if

your prescription drug contains an MAOI, ask a doctor or

pharmacist before taking this product.

• in children under 12 years of age

OTC - ASK DOCTOR SECTION

Ask a doctor before use if

• the stomach bleeding warning applies to you

• you have a history of stomach problems, such as heartburn

• you have high blood pressure, heart disease, liver cirrhosis,kidney disease

asthma,thyroid disease,diabetes, have trouble urinating due to an enlarged prostate gland, or had a stroke

• you are taking a diuretic

• you have problems or serious side effects from taking pain

relievers or fever reducers

OTC - ASK DOCTOR/PHARMACIST SECTION

Ask a doctor or pharmacist before use if you are

• under a doctor’s care for any serious condition

• taking aspirin for heart attack or stroke, because naproxen may decrease this benefit of aspirin

• taking any other drug

OTC - WHEN USING SECTION

When using this product

• take with food or milk if stomach upset occurs

OTC - STOP USE SECTION

Stop use and ask a doctor if

• you experience any of the following signs of stomach

bleeding:

• feel faint • vomit blood • have bloody or black stools

• have stomach pain that does not get better

•you have symptoms of heart problems or stroke:

• chest pain • trouble breathing

• weakness in one part or side of body

• slurred speech • leg swelling

• redness or swelling is present in the painful area

• any new symptoms appear

• fever gets worse or lasts more than 3 days

• you have difficulty swallowing or the caplet feels stuck in

your throat

• you get nervous, dizzy, or sleepless

• nasal congestion lasts more than 7 days

OTC - PREGNANCY OR BREAST FEEDING SECTION

If pregnant or breast-feeding, ask a health professional before

use. It is especially important not to use naproxen sodium

during the last 3 months of pregnancy unless definitely directed

to do so by a doctor because it may cause problems in the

unborn child or complications during delivery.

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children. In case of overdose, get

medical help or contact a Poison Control Center right away.

Directions

DOSAGE & ADMINISTRATION SECTION

Directions • do not take more than directed

• the smallest effective dose should be used

• swallow whole; do not crush or chew • drink a full glass of water with each dose

• adults and children 12 years and older : 1 caplet every

12 hours; do not take more than 2 caplets in 24 hours • children under 12 years: do not use

Other information

OTHER SAFETY INFORMATION

Other information

• each caplet contains: sodium 21 mg

• meets USP Dissolution Test 2

• store at 20-25°C (68-77°F)

• store in a dry place

INACTIVE INGREDIENT SECTION

Inactive ingredients colloidal silicon dioxide,

hypromellose, lactose monohydrate, magnesium stearate,

microcrystalline cellulose, polyethylene glycol, polysorbate 80,

povidone, talc, titanium dioxide

OTC - QUESTIONS SECTION

Questions or comments? 1-800-986-0369

Carton 10 count

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Aleve DAleve D

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1367426naproxen sodium 220 MG / pseudoephedrine HCl 120 MG 12HR Extended Release Oral TabletPSN8
136742612 HR naproxen sodium 220 MG / pseudoephedrine hydrochloride 120 MG Extended Release Oral TabletSCD8
1367426naproxen sodium 220 MG / pseudoephedrine hydrochloride 120 MG 12 HR Extended Release Oral TabletSY8

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NAPROXEN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20191108
PSEUDOEPHEDRINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
fef6ad89-235f-4274-ba49-a8e53642473eProduct name220250225
87fed3e6-8fba-48ef-96b0-3a7fb54b96ffProduct name320230306
ba088a92-ab5e-b2d4-e908-f5ea691b7587Product name720210201
b5fdaaec-7251-4da6-9cb2-4e9e76939ec8Product name120200623
e76dbbc1-775d-722c-08ff-ed45e8a80defProduct name320181002
0fdb98e2-b951-a1ce-5715-2b187ba500efProduct name420170718
e974e22d-8688-7d92-1e87-40c1079e170cProduct name320151125
e8718272-64cb-4436-969b-176c3067c8f4Product name120150609
30c51294-7ae9-8007-7de6-58222684a0beProduct name120140508
4f26f669-fc6c-40ef-9e26-1c7b2390ee66Product name120140508
6f4f4521-fd56-1ae6-888b-3b021bd75c7cProduct name120140508
70a83adc-6047-bbea-5a08-dfd304aa47d2Product name120140508
858ce051-9941-aafc-8c7c-44a8e0227463Product name120140508
b893258d-0942-3d8a-3411-056ea0788ff5Product name120140508
ce67e27d-1d21-5465-4409-b0662dd99d4dProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0280-6090-10Aleve-D Sinus and Cold10 in 1 BLISTER PACKTABLET108
0280-6090-10Aleve-D Sinus and Cold1 in 1 CARTONTABLET18
0280-6090-20Aleve-D Sinus and Cold10 in 1 BLISTER PACKTABLET108
0280-6090-20Aleve-D Sinus and Cold2 in 1 CARTONTABLET28

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0280-6090-10EA - Each0280-609018dd7189-618f-4f5c-90fa-15c586f65fe012018-11-06
0280-6090-20EA - Each0280-6090dfd25e28-db27-4582-be80-d137007f164f12017-10-13

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 17 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0280-60900280-6090-10, 0280-6090-20

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML · Source PDF

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDENAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1784e616aacf4f…
2026-08-18 06:07:402026-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1731067a03dcf5…
2025-08-23 18:47 UTC2025-08A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-176a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-172680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-175bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-171e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-178072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-175c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-175d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-174b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-1774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-1787673890dc5c…
2021-03-12 10:30 UTC2021-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-175aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-178869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-173f01610625f2…
2019-09-15 20:21 UTC2019-09A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDEEQ 200MG BASE;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17b00525d2431f…
2019-07-19 19:46 UTC2019-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDEEQ 200MG BASE;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-176a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-171c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-179b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-173f0d92c62455…
2023-05-13 08:27 UTC2023-05A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17053a50430f4f…
2023-01-26 05:58 UTC2023-01A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-173bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-173a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Aleve-D Sinus and ColdNAPROXEN SODIUM, PSEUDEOEPHEDRINE HYDROCHLORIDEBayer HealthCare LLC.599ea6c8-03ad-536e-e053-2991aa0a83a32025-12-04WarningsExact identifier
ndc (package): 0280-6090-10
ndc (package): 0280-6090-20
ndc (product): 0280-6090
ndc11 (package): 00280609020
ndc11 (package): 00280609010
spl id: 4526c387-9c6e-1a47-e063-6394a90a21da
spl set id: 599ea6c8-03ad-536e-e053-2991aa0a83a3

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.